Andreas Forsland on investment
From The Future of Brain-Computer Interfaces and Human-Machine Integration (With Andreas Forsland)-Ep#186 · · Future Tech and Foresight Podcast
“Most of the investment, including government grants, venture capital, and sovereign wealth funds, is being poured into healthcare use cases for BCIs. While consumer wellness applications like mental focus and sleep improvement exist, the real opportunity and money over the next 10 to 20 years will be in legitimate healthcare applications.”
On , Andreas Forsland, Cofounder at Cognixion, spoke about investment during The Future of Brain-Computer Interfaces and Human-Machine Integration (With Andreas Forsland)-Ep#186 on Future Tech and Foresight Podcast.
About Andreas Forsland
Andreas Forsland, cofounder and CEO of Cognixion, has been discussing the company’s development of a non-invasive brain-computer interface (BCI) headset that combines EEG sensing with augmented reality. Forsland stated that the device, which received FDA Breakthrough Device designation, is designed to assist people with conditions such as ALS, stroke, and traumatic brain injury by enabling communication through a combination of head motion, eye tracking, and brain signals. He noted that the company has begun commercially shipping a research platform called the Axon R, which is in use at institutions including Johns Hopkins, Northwell Health, and Mass General Hospital, and that a consumer version, the Cognixion One, is still undergoing regulatory review. Forsland has emphasized that advances in AI and machine learning have improved the quality of non-invasive EEG, which he described as historically considered poor and unreliable. He has argued that the field’s focus on information transfer rate is less relevant than “degrees of freedom” for evaluating BCI performance, and that non-invasive systems can cannibalize many use cases of implantable BCIs. Forsland has also stated that the company’s long-term goal is to create a platform for health systems to develop and commercialize clinically validated applications for neurology, diagnostics, and therapeutics, and that the biggest barrier to BCI adoption is not hardware but the creation of compelling user experiences and insurance coverage.